PerkinElmer Stock

$88.23

0.38% today

NYSE, Aug 01, 10:00 pm CET

ISIN

US7140461093

Symbol

RVTY

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

PerkinElmer Stock price

$87.90

-31.01 26.08% 5Y

NYSE, Closing price Thu, Jul 31 2025

-2.95 3.25%

ISIN

US7140461093

Symbol

RVTY

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$10.4b

Enterprise Value

$12.4b

Net debt

$2.0b

Cash

$1.1b

Shares outstanding

119.4m

Valuation (TTM | estimate)

P/E

36.9 | 17.5

P/S

3.7 | 3.6

EV/Sales

4.5 | 4.3

EV/FCF

23.6

P/B

1.4

Dividends

DPS

$0.28

Yield 1Y | 5Y

0.3% | 0.2%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

12.7% | 6.9%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$2.8b | $2.9b

EBITDA

$819.0m | $894.1m

EBIT

$401.5m | $814.8m

Net Income

$286.6m | $600.7m

Free Cash Flow

$524.1m

Growth (TTM | estimate)

Revenue

1.6% | 5.6%

EBITDA

2.4% | 5.3%

EBIT

8.7% | 93.5%

Net Income

91.5% | 122.2%

Free Cash Flow

439.7%

Financial Health

Equity Ratio

61.9%

Return on Equity

3.5%

ROCE

3.4%

ROIC

Debt/Equity

0.4

EPS

$2.4

FCF per Share

$4.4

Short interest

7.3%

Employees

11k

Rev per Employee

$250.0k

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

PerkinElmer Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a PerkinElmer forecast:

17x Buy

65%

8x Hold

31%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a PerkinElmer forecast:

Buy

65%

Hold

31%

Sell

Analyst Estimates with Stock Price Targets

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,770 2,770	2% 2% 100%
- Direct Costs	1,212 1,212	0% 0% 44%
Gross Profit	1,558 1,558	3% 3% 56%
- Selling and Administrative Expenses	961 961	4% 4% 35%
- Research and Development Expense	200 200	5% 5% 7%
EBITDA	819 819	2% 2% 30%
- Depreciation and Amortization	417 417	3% 3% 15%
EBIT (Operating Income) EBIT	402 402	9% 9% 14%
Net Profit	287 287	92% 92% 10%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PerkinElmer Stock News

Neutral

Seeking Alpha

●

4 days ago

Revvity Q2: Headwinds From China And Customers, Buy On Weakness

Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines Revvity's portfolio, allowing greater investment in specialized diagnostics and software, which are expected to drive future growth. While facing weak academic/government demand and China headwinds,...

Negative

Investopedia

●

4 days ago

Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook

Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China.

Positive

Investopedia

●

4 days ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

U.S. equities were mhigher at midday after President Donald Trump and European Commission President Ursula von der Leyen announced a new trade agreement between the U.S. and the European Union. The Dow Jones Industrial Average, Nasdaq, and S&P 500 all rose.

More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office	United States
CEO	Prahlad Singh
Employees	11,000
Founded	1937
Website	www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now